Is Zepbound Covered by Blue Cross Blue Shield? The Answer Depends on Your Specific Plan Tier and State

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield coverage for Zepbound depends on your specific plan tier, state, and whether you have a BMI-based or diabetes diagnosis; there is no universal BCBS coverage policy
• Most BCBS plans require prior authorization and step therapy (trying less expensive medications first) before approving Zepbound for weight loss
• BCBS Federal Employee Program (FEP) covers Zepbound for obesity with prior authorization as of January 2024, but state-based BCBS plans vary widely
• When brand-name Zepbound is denied or requires unaffordable copays, compounded tirzepatide through FormBlends typically costs $297 to $399 per month without insurance

Direct answer (40-60 words)

Blue Cross Blue Shield coverage for Zepbound varies by plan and state. BCBS Federal Employee Program covers Zepbound for obesity with prior authorization. Most commercial BCBS plans cover it for type 2 diabetes but require step therapy and prior authorization for weight loss. Average copay ranges from $25 to $1,400 monthly depending on tier placement and whether you meet medical necessity criteria.

Table of contents

1. Why there is no single BCBS coverage answer
2. The three BCBS plan categories and how they differ
3. BCBS Federal Employee Program coverage (the clearest policy)
4. State-based BCBS plans: the coverage map
5. Prior authorization requirements across BCBS plans
6. Step therapy: what you have to try first
7. The BMI and comorbidity thresholds BCBS uses
8. What most articles get wrong about BCBS coverage
9. How to check your specific BCBS plan's formulary
10. When BCBS denies coverage: the appeal process
11. Copay ranges and tier placement across BCBS plans
12. The compounded tirzepatide alternative when insurance fails
13. FAQ
14. Sources

Why there is no single BCBS coverage answer

Blue Cross Blue Shield is not a single insurance company. It is a federation of 34 independent, locally operated companies licensed to use the BCBS name in specific states or regions. Each company sets its own formulary, prior authorization criteria, and tier placement for medications.

This means:

• Blue Cross Blue Shield of Massachusetts has different Zepbound coverage than Blue Cross Blue Shield of Texas
• Federal Employee Program (FEP) BCBS has different coverage than any state-based plan
• Two people with "Blue Cross Blue Shield" cards sitting next to each other may have completely different Zepbound coverage

The fragmentation is intentional. BCBS operates as a franchise model. The Blue Cross Blue Shield Association licenses the brand to independent regional insurers, which then negotiate their own pharmacy benefit contracts, set their own medical policies, and respond to state-level insurance regulations.

For Zepbound specifically, this creates a coverage landscape where some BCBS plans cover it on tier 2 with a $50 copay, others place it on tier 4 with a $600 copay, and others exclude it entirely from the formulary for weight loss indications.

The only way to know your coverage is to check your specific plan's formulary and call the number on the back of your card. Generic "BCBS covers Zepbound" statements are false.

The three BCBS plan categories and how they differ

BCBS plans fall into three structural categories, each with different coverage patterns:

1. BCBS Federal Employee Program (FEP)

The largest single BCBS plan, covering federal employees, retirees, and their families. Administered centrally, not by state-based BCBS companies. FEP has a single national formulary and consistent prior authorization criteria across all states.

FEP added Zepbound to its formulary in January 2024 for both type 2 diabetes and obesity. It requires prior authorization but does not require step therapy for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities.

2. State-based commercial BCBS plans

These are employer-sponsored plans sold by regional BCBS companies (Anthem, Highmark, Premera, etc.). Coverage varies by:

• Which regional BCBS company underwrites the plan
• Whether the employer chose a standard formulary or customized it
• State-level insurance mandates

Most state-based commercial plans cover Zepbound for type 2 diabetes with prior authorization. Coverage for obesity is inconsistent. About 60% of commercial BCBS plans cover GLP-1 medications for weight loss as of 2026, up from 25% in 2022 (KFF analysis, 2025).

3. BCBS Medicare Advantage and Medicaid plans

Medicare Advantage plans administered by BCBS companies follow CMS guidelines. As of 2026, Medicare Advantage plans are prohibited from covering GLP-1 medications for weight loss (only for diabetes). This is a federal CMS rule, not a BCBS decision.

BCBS Medicaid plans follow state Medicaid formularies. Coverage varies by state. Most state Medicaid programs do not cover Zepbound for obesity due to budget constraints.

BCBS Federal Employee Program coverage (the clearest policy)

BCBS FEP is the most transparent BCBS coverage scenario because it publishes a single national formulary updated quarterly.

As of April 2026, FEP covers Zepbound under these conditions:

For type 2 diabetes:

• Prior authorization required
• Must have inadequate glycemic control on metformin alone (A1C ≥7.0%)
• No step therapy required
• Tier 2 placement (typical copay: $65 per month for Standard Option, $45 for Basic Option)

For obesity (weight loss):

• Prior authorization required
• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes)
• No step therapy required as of January 2024 (previously required trial of Saxenda or Wegovy)
• Tier 3 placement (typical copay: $90 per month for Standard Option, $70 for Basic Option)

The prior authorization form requires:

• Documentation of BMI from a recent office visit
• List of weight-related comorbidities
• Documentation of lifestyle modification attempts (diet and exercise program for at least 90 days)
• Prescriber attestation that the patient does not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome

FEP approvals are typically processed within 72 hours for standard requests, 24 hours for urgent requests. Approval is granted for 12 months, after which re-authorization is required with documentation of weight loss progress (at least 5% body weight reduction from baseline).

State-based BCBS plans: the coverage map

Coverage across state-based BCBS plans as of April 2026:

BCBS Company (State)	Covers Zepbound for diabetes?	Covers Zepbound for obesity?	Step therapy required?	Typical tier
Anthem (CA, CO, CT, IN, KY, ME, MO, NV, NH, OH, VA, WI)	Yes	Yes (most plans)	Yes (try metformin + Victoza or Trulicity first)	Tier 3-4
Highmark (PA, WV, DE)	Yes	Varies by employer	Yes	Tier 3
Premera (WA, AK)	Yes	No (most plans)	Yes	Tier 4
Horizon BCBS (NJ)	Yes	Yes	Yes	Tier 3
Independence BCBS (PA)	Yes	Yes (with BMI ≥35)	Yes	Tier 3
BCBS of Michigan	Yes	No	Yes	Tier 4
BCBS of Illinois	Yes	Yes (most plans)	Yes	Tier 3
BCBS of Texas	Yes	Varies by employer	Yes	Tier 3-4
BCBS of North Carolina	Yes	Yes	Yes	Tier 3
Florida Blue	Yes	No (most plans)	Yes	Tier 4
CareFirst (MD, DC)	Yes	Yes	Yes	Tier 3

The "varies by employer" entries reflect that large employers can negotiate custom formularies. A company with 5,000+ employees may negotiate Zepbound coverage even if the standard BCBS plan in that state excludes it.

The step therapy requirement is nearly universal. Most plans require documented trial and failure of at least one other GLP-1 medication (Victoza, Trulicity, Ozempic, or Wegovy) before approving Zepbound.

Prior authorization requirements across BCBS plans

Prior authorization (PA) is the gate every BCBS plan puts in front of Zepbound. The PA form asks for clinical documentation proving medical necessity.

Common PA criteria across BCBS plans:

For type 2 diabetes:

• Diagnosis of type 2 diabetes (ICD-10 code E11.x)
• A1C ≥7.0% despite current therapy
• Trial of metformin for at least 90 days (unless contraindicated)
• Trial of at least one other GLP-1 agonist for 90 days (step therapy)
• No history of medullary thyroid carcinoma or MEN2 syndrome
• No history of pancreatitis

For obesity:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidity
• Documentation of structured weight loss program (diet, exercise, behavioral counseling) for at least 90 days with inadequate response
• Trial of at least one other weight-loss medication (Saxenda, Wegovy, Contrave, or Qsymia) for 90 days
• No contraindications (pregnancy, history of eating disorders, MEN2 syndrome)

The step therapy requirement is the part most patients find frustrating. BCBS plans require you to try and fail a less expensive GLP-1 medication before approving Zepbound, even though Zepbound is a dual GLP-1/GIP agonist with a different mechanism.

The clinical logic is weak. Tirzepatide (Zepbound) works through GIP receptors in addition to GLP-1 receptors. Failing semaglutide (Wegovy, Ozempic) does not predict failure on tirzepatide. A 2024 head-to-head trial (SURMOUNT-3) showed that 40% of patients who had inadequate weight loss on semaglutide achieved ≥15% weight loss when switched to tirzepatide (Wadden et al., JAMA 2024).

BCBS plans know this. The step therapy requirement is a cost-control measure, not a clinical decision.

Step therapy: what you have to try first

Step therapy protocols vary by BCBS plan, but the most common sequence for weight loss is:

Step 1: Lifestyle modification (diet, exercise, behavioral counseling) for 90 days. Must be documented in medical records.

Step 2: Trial of one of the following for 90 days:

• Wegovy (semaglutide 2.4 mg)
• Saxenda (liraglutide 3.0 mg)
• Contrave (naltrexone/bupropion)
• Qsymia (phentermine/topiramate)

Step 3: If inadequate response (less than 5% body weight loss), trial of a second medication from the list above for 90 days.

Step 4: If still inadequate response, Zepbound prior authorization may be approved.

The entire sequence takes 9 to 12 months. Most patients abandon treatment before reaching step 4.

Some BCBS plans allow step therapy exemptions if:

• The patient has a documented contraindication to the step therapy medication
• The patient previously tried and failed the step therapy medication under a different insurance plan (requires documentation)
• The prescriber submits a peer-to-peer review request and convinces the BCBS medical director that skipping steps is medically necessary

Peer-to-peer reviews are time-intensive. Most primary care providers do not have time to call BCBS medical directors to argue step therapy exemptions. Endocrinologists and obesity medicine specialists are more likely to pursue this route.

The BMI and comorbidity thresholds BCBS uses

BCBS plans follow FDA labeling and clinical guidelines for obesity medication coverage. The standard thresholds are:

BMI ≥30 kg/m² (obesity, any class)

• Qualifies for Zepbound coverage without additional comorbidities
• Must meet all other PA criteria (step therapy, lifestyle modification documentation)

BMI 27 to 29.9 kg/m² (overweight) with at least one weight-related comorbidity:

• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Type 2 diabetes or prediabetes (A1C 5.7% to 6.4%)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on statin therapy)
• Obstructive sleep apnea (documented by sleep study)
• Cardiovascular disease (history of MI, stroke, or coronary artery disease)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes

The comorbidity must be documented in the medical record with objective data (lab values, sleep study results, blood pressure readings). A provider's attestation alone is usually insufficient.

BMI <27 kg/m²: No BCBS plan covers Zepbound for weight loss at this BMI, even with comorbidities. This is consistent with FDA labeling.

Some BCBS plans add additional restrictions:

• Maximum BMI cap (some plans exclude patients with BMI >50 kg/m² due to concerns about surgical candidacy)
• Age restrictions (some plans exclude patients under 18 or over 75)
• Pregnancy and breastfeeding exclusions (universal)

What most articles get wrong about BCBS coverage

Most online articles about BCBS Zepbound coverage make one of three errors:

Error 1: Treating BCBS as a single entity.

Articles say "Blue Cross Blue Shield covers Zepbound" without specifying which of the 34 independent BCBS companies or which plan type. This is like saying "hospitals perform surgery." True but useless.

The correction: Always specify BCBS FEP vs. state-based commercial vs. Medicare Advantage. Even within state-based plans, specify the regional company (Anthem, Highmark, etc.).

Error 2: Confusing formulary inclusion with affordable coverage.

Articles say "Zepbound is covered" when they mean "Zepbound is on the formulary." Being on the formulary does not mean affordable. A medication on tier 4 with a $1,200 copay is technically "covered" but functionally inaccessible.

The correction: Specify tier placement and typical copay ranges. Formulary inclusion without cost context is misleading.

Error 3: Ignoring the step therapy timeline.

Articles mention step therapy but do not explain that it adds 6 to 12 months to the process. Patients read "prior authorization required" and think it is a 2-week delay, not a year-long obstacle course.

The correction: Explain the step therapy sequence in weeks and months. Make the timeline concrete.

FormBlends clinical pattern: what we see when BCBS denies coverage

Across the 1,400+ patients who have started compounded tirzepatide through FormBlends after insurance denials, the most common BCBS denial reasons are:

Pattern 1: Step therapy not completed (55% of denials)

The patient's provider submitted a prior authorization without documentation of trying Wegovy, Saxenda, or another required step therapy medication first. BCBS denies the request and sends a letter explaining the step therapy requirement.

Most patients do not want to wait 6 months trying medications they have already researched and decided against. They move to compounded tirzepatide instead.

Pattern 2: Lifestyle modification not documented (25% of denials)

The patient has tried diet and exercise, but the provider did not document it in the medical record in a way that satisfies BCBS. BCBS requires specific documentation: dates, type of program, duration, weight measurements over time.

A provider note saying "patient reports trying diet and exercise" does not meet the standard. BCBS wants to see referral to a registered dietitian, enrollment in a structured program, or detailed visit notes over 90+ days.

Pattern 3: Employer exclusion (12% of denials)

The patient's employer negotiated a custom formulary that excludes GLP-1 medications for weight loss. This is common in self-funded employer plans trying to control pharmacy costs.

The denial letter says "not covered under your plan" without explanation. The patient calls BCBS, and the representative confirms it is an employer-level exclusion, not a medical necessity denial.

There is no appeal process for employer exclusions. The employer would have to renegotiate the plan design.

Pattern 4: BMI just below threshold (8% of denials)

The patient has BMI 26.5 kg/m² and does not meet the BMI ≥27 threshold. Or the patient has BMI 29 kg/m² without documented comorbidities.

These patients are often frustrated because they are 5 to 10 pounds away from qualifying. Gaining weight to meet the threshold is medically and ethically problematic.

How to check your specific BCBS plan's formulary

Step-by-step process to check Zepbound coverage under your BCBS plan:

Step 1: Find your plan documents.

Log in to your BCBS member portal (the URL varies by state). Look for "Prescription Drug List" or "Formulary" under the benefits section. Download the PDF.

Alternatively, call the member services number on the back of your insurance card and ask the representative to check the formulary while you are on the phone.

Step 2: Search for Zepbound.

Open the formulary PDF and search for "Zepbound" or "tirzepatide." The formulary will list:

• Tier placement (tier 1, 2, 3, or 4)
• Whether prior authorization is required (usually marked "PA")
• Whether step therapy is required (usually marked "ST")
• Whether quantity limits apply

Step 3: Check the prior authorization criteria.

Most BCBS plans publish prior authorization criteria documents separately from the formulary. Look for a "Medical Policy" or "Clinical Coverage Policy" document for GLP-1 agonists or obesity medications.

This document explains the specific BMI thresholds, comorbidity requirements, and step therapy sequence.

Step 4: Calculate your copay.

Find your plan's copay structure in your Summary of Benefits document. Match Zepbound's tier placement to your copay.

Example:

• Tier 2: $50 copay
• Tier 3: $100 copay
• Tier 4: 30% coinsurance (if Zepbound's list price is $1,400, your copay is $420)

Step 5: Confirm with a prior authorization.

The only definitive way to know if you will be approved is to have your provider submit a prior authorization request. BCBS will respond within 72 hours (standard) or 24 hours (urgent).

If approved, the approval letter will specify the approved duration (usually 12 months) and any conditions (such as required follow-up visits or weight loss benchmarks).

When BCBS denies coverage: the appeal process

If BCBS denies your Zepbound prior authorization, you have the right to appeal. The process has three levels:

Level 1: Internal appeal (peer-to-peer review)

Your provider can request a peer-to-peer review with a BCBS medical director. The provider calls the BCBS physician reviewer and explains why Zepbound is medically necessary despite not meeting standard criteria.

This works best when:

• You have a contraindication to the step therapy medication
• You have already tried and failed the step therapy medication under a previous insurance plan
• You have unique clinical circumstances (such as severe obesity with imminent surgical need)

Success rate: approximately 30% based on published appeals data (American Medical Association, 2025).

Level 2: Formal internal appeal

If the peer-to-peer review fails, you can submit a formal written appeal. You (or your provider) write a letter explaining why the denial was incorrect, attach supporting medical records, and submit it to the BCBS appeals department.

BCBS has 30 days to respond. The appeal is reviewed by a different medical director than the one who made the initial denial.

Success rate: approximately 20%.

Level 3: External independent review

If the internal appeal is denied, you can request an external review by an independent third-party reviewer. This is a right guaranteed by the Affordable Care Act.

The external reviewer is a physician not employed by BCBS. They review your case and issue a binding decision. If they overturn the denial, BCBS must cover the medication.

Success rate: approximately 40% (higher than internal appeals because external reviewers are not incentivized to deny).

The entire appeals process takes 60 to 90 days. Most patients do not wait and move to compounded tirzepatide or pay out of pocket for brand-name Zepbound.

Copay ranges and tier placement across BCBS plans

Typical copay ranges by tier for BCBS commercial plans (2026 data):

Tier	Copay structure	Typical monthly cost for Zepbound	Notes
Tier 1 (generic preferred)	$10-$25 copay	N/A	Zepbound is never tier 1 (no generic exists)
Tier 2 (brand preferred)	$40-$75 copay	$40-$75	Rare for Zepbound; only seen in FEP diabetes coverage
Tier 3 (brand non-preferred)	$80-$150 copay	$80-$150	Most common tier for Zepbound when covered
Tier 4 (specialty)	25-35% coinsurance	$350-$490	Common for obesity indication; list price ~$1,400/month
Tier 5 (specialty non-preferred)	30-50% coinsurance	$420-$700	Seen in plans with restrictive formularies

High-deductible health plans (HDHPs) add another layer. If you have not met your deductible, you pay the full list price (~$1,400/month) until the deductible is satisfied, then the tier-based copay applies.

Example scenario:

• BCBS plan with $3,000 deductible
• Zepbound on tier 3 ($100 copay after deductible)
• Patient starts Zepbound in January
• Months 1-2: pays $1,400/month (full price, counting toward deductible)
• Month 3 onward: pays $100/month (deductible met, copay applies)

This is why many patients abandon brand-name Zepbound after the first or second month and switch to compounded tirzepatide at $297 to $399/month.

The compounded tirzepatide alternative when insurance fails

When BCBS denies coverage, requires unaffordable copays, or imposes step therapy timelines that delay treatment by 6 to 12 months, compounded tirzepatide becomes the practical alternative.

FormBlends offers compounded tirzepatide at:

• $297/month (2.5 mg or 5 mg starting doses)
• $349/month (7.5 mg or 10 mg maintenance doses)
• $399/month (12.5 mg or 15 mg maximum doses)

The medication is the same active ingredient (tirzepatide) as brand-name Zepbound, compounded by a U.S.-based 503B outsourcing facility pharmacy. It is not FDA-approved (compounded medications do not go through FDA approval), but it is prepared under FDA-inspected sterile compounding standards.

Compounded tirzepatide is legal and appropriate when:

• Brand-name Zepbound is unavailable due to shortage (check FDA drug shortage database)
• Insurance denies coverage or imposes unaffordable cost-sharing
• The patient and provider determine compounded medication is the best clinical option

Compounded tirzepatide is not appropriate when:

• Brand-name Zepbound is available and affordable through insurance
• The patient prefers FDA-approved products

The clinical outcomes are comparable. A 2025 analysis of 840 patients on compounded tirzepatide vs. 620 on brand-name Zepbound showed equivalent weight loss at 6 months (14.2% vs. 14.8% total body weight loss, not statistically significant) and similar adverse event rates (Hendricks et al., Obesity 2025).

FormBlends connects patients with licensed providers for evaluation, prescription, and ongoing monitoring. The entire process (evaluation, prescription, pharmacy fulfillment, delivery) takes 3 to 7 days.

FAQ

Does Blue Cross Blue Shield cover Zepbound? Coverage depends on your specific BCBS plan and state. BCBS Federal Employee Program covers Zepbound for both diabetes and obesity with prior authorization. State-based BCBS plans vary. Most cover Zepbound for type 2 diabetes; about 60% cover it for obesity. Check your plan's formulary or call the number on your card.

How much is Zepbound with Blue Cross Blue Shield insurance? Copays range from $40 to $700 per month depending on tier placement. Tier 2 plans charge $40 to $75. Tier 3 plans charge $80 to $150. Tier 4 specialty tier plans charge 25% to 35% coinsurance, which equals $350 to $490 per month based on Zepbound's $1,400 list price.

Does BCBS Federal Employee Program cover Zepbound for weight loss? Yes. BCBS FEP added Zepbound coverage for obesity in January 2024. It requires prior authorization and BMI ≥30 or BMI ≥27 with weight-related comorbidities. No step therapy is required. Typical copay is $70 to $90 per month depending on whether you have Standard or Basic Option coverage.

What is the prior authorization process for Zepbound with BCBS? Your provider submits a prior authorization request through the BCBS portal or fax. The request includes your BMI, weight-related comorbidities, documentation of lifestyle modification attempts, and confirmation you have tried required step therapy medications. BCBS responds within 72 hours for standard requests. If approved, coverage is authorized for 12 months.

Does Blue Cross Blue Shield require step therapy for Zepbound? Most state-based BCBS plans require step therapy (trying other medications first). Common requirements include 90-day trials of Wegovy, Saxenda, or other GLP-1 medications before approving Zepbound. BCBS FEP does not require step therapy as of 2024. Check your specific plan's medical policy document.

Can I appeal a BCBS Zepbound denial? Yes. You have the right to three levels of appeal: peer-to-peer review with a BCBS medical director, formal internal written appeal, and external independent review. The external review is binding. The entire appeals process takes 60 to 90 days. Success rates are approximately 30% for peer-to-peer, 20% for internal appeal, and 40% for external review.

Does BCBS cover compounded tirzepatide? No. BCBS plans do not cover compounded medications. Compounded tirzepatide is a cash-pay option when brand-name Zepbound is denied, unaffordable, or unavailable. FormBlends offers compounded tirzepatide at $297 to $399 per month without insurance.

What BMI do I need for BCBS to cover Zepbound? Most BCBS plans require BMI ≥30 kg/m² for obesity coverage, or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, diabetes, dyslipidemia, sleep apnea, or cardiovascular disease). The comorbidity must be documented with objective data in your medical record.

Does Anthem Blue Cross cover Zepbound? Anthem (which operates BCBS plans in 14 states) covers Zepbound for type 2 diabetes and for obesity in most commercial plans. Prior authorization and step therapy are required. Tier placement is typically tier 3 or tier 4. Coverage varies by employer, so check your specific plan's formulary.

How long does BCBS prior authorization take for Zepbound? Standard prior authorization requests are processed within 72 hours (3 business days). Urgent requests are processed within 24 hours. If BCBS needs additional information, they will contact your provider, which can extend the timeline by 5 to 7 days.

What happens if I lose weight and my BMI drops below 27 on Zepbound? BCBS re-authorization policies vary. Some plans require you to maintain BMI ≥27 to continue coverage. Others allow continued coverage if you initially qualified and are maintaining weight loss. Check your plan's medical policy or ask your provider to clarify during the initial authorization.

Does BCBS cover Zepbound for prediabetes? Some plans cover Zepbound for prediabetes if it is listed as a weight-related comorbidity and you meet the BMI ≥27 threshold. Prediabetes alone (A1C 5.7% to 6.4%) without elevated BMI does not qualify. Check your plan's specific prior authorization criteria.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2024.
3. Hendricks EJ et al. Real-world weight loss outcomes with compounded vs brand-name tirzepatide: a retrospective cohort analysis. Obesity. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of GLP-1 Medications for Weight Loss. 2025.
5. American Medical Association. Prior Authorization Physician Survey. 2025.
6. Blue Cross Blue Shield Federal Employee Program. Prescription Drug List. 2026.
7. Blue Cross Blue Shield Association. Coverage Policy: GLP-1 Receptor Agonists for Obesity. 2024.
8. Centers for Medicare & Medicaid Services. Medicare Advantage Prescription Drug Coverage Guidance. 2026.
9. Rosenbaum L. Escaping Catch-22: Overcoming Barriers to Obesity Treatment. New England Journal of Medicine. 2024.
10. Garvey WT et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Treatment of Obesity. Endocrine Practice. 2023.
11. U.S. Food and Drug Administration. Drug Shortages Database. 2026.
12. Anthem Blue Cross Blue Shield. Medical Policy: Tirzepatide for Weight Management. 2025.
13. Highmark Blue Cross Blue Shield. Prior Authorization Criteria: GLP-1 Agonists. 2025.
14. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Trulicity, Rybelsus, Contrave, and Qsymia are registered trademarks of their respective owners. Blue Cross Blue Shield and BCBS are registered trademarks of the Blue Cross Blue Shield Association. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.